Estimated cumulative incidences of de novo HCC at two and four years after the initiation of DAA therapy were 11.7% and 23.5% in the Ang2 ≥ 464 pg/mL group and 3.4% and 6.6% in the Ang2 < 464 pg/mL group, respectively. This evidence concerns the gene ANGPT2 and hepatocellular carcinoma.